Thalidomide-PEG3-NH2 is a high-purity E3 Ligase Ligand-Linker Conjugate, specifically designed for use in PROTAC (Proteolysis Targeting Chimera) drug development. This compound features thalidomide—a cereblon (CRBN) E3 ubiquitin ligase recruiter—connected via a triethylene glycol (PEG3) spacer to a terminal amine (NH2) group. The PEG3 linker provides optimal flexibility and hydrophilicity, facilitating efficient conjugation to target-binding ligands for synthesizing bifunctional PROTAC molecules. Thalidomide-PEG3-NH2 is widely used to engineer new PROTACs for targeted protein degradation in research and preclinical studies, expediting the exploration of novel therapeutics for oncology and other disease areas. As part of the "E3 Ligase Ligand-Linker Conjugates" category, this product empowers scientists to generate custom degraders by selectively harnessing the ubiquitin-proteasome pathway.
Structure of 1957236-10-0
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Thalidomide-PEG3-NH2 is an advanced E3 ligase ligand-linker conjugate designed for the targeted protein degradation approach in chemical biology and drug discovery. By combining a thalidomide-based cereblon (CRBN) ligand with a flexible PEG3 linker and a terminal amine, this molecule serves as a crucial building block for PROTAC (Proteolysis Targeting Chimera) design. Its structure enables researchers to create bifunctional molecules that harness the ubiquitin-proteasome system for selective protein degradation, representing a transformative strategy in therapeutic development.
Mechanism
Thalidomide-PEG3-NH2 operates as a functional E3 ligase ligand-linker conjugate. The thalidomide moiety selectively binds to the CRBN E3 ubiquitin ligase, a key component of the body's cellular protein quality control machinery. The PEG3 linker provides optimal spacing and solubility, minimizing steric hindrance and enhancing the overall efficacy of PROTAC molecules. The terminal amine group allows for straightforward conjugation to target protein-binding ligands, yielding fully functional PROTACs. Upon administration, the resulting PROTAC molecule induces proximity between the target protein and the CRBN ligase complex, facilitating ubiquitination and subsequent proteasomal degradation of the target protein.
Applications
Thalidomide-PEG3-NH2 is primarily used in the synthesis of PROTACs for targeted protein degradation studies. It enables the rapid development of novel therapeutics for cancer, neurodegenerative diseases, and autoimmune disorders by facilitating the removal of disease-causing proteins. Researchers utilize this product for structure-activity relationship (SAR) studies, high-throughput screening, and the creation of bespoke PROTAC libraries. Its modular design streamlines the optimization of linker length and chemical properties, supporting advanced research in chemical biology, drug discovery, and next-generation therapeutics.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.